Zuegel Martin 4

What Happened

• Martin Zuegel, Interim CEO and Director of AC Immune SA (ACIU), was granted compensation awards on June 11, 2026: 33,136 restricted share units (RSUs) and options covering 77,778 shares. Both grants were recorded at $0.00 (awards under the company's 2016 Stock Option and Incentive Plan), so no cash was exchanged.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 15, 2026 (timely filing).
• Awards: 33,136 RSUs (grant under SOIP) and 77,778 share options (derivative grant).
• Price: $0.00 per unit (award/grant), total purchase value $0.
• Vesting: the 77,778 share options will fully vest on June 10, 2027.
• Amount owned following the report (per footnote): comprised of 71,408 common shares underlying outstanding restricted share units.
• Transaction code: A = Award/Grant under the company incentive plan.

Context

• RSUs and stock options are typical equity compensation — they do not require an immediate cash outlay and generally vest over time; options will vest in full on 2027-06-10 per the filing.
• These grants are routine executive compensation and do not by themselves indicate a buy/sell trading signal.